MARKET

ENGNW

ENGNW

enGene Therapeutics Inc
NASDAQ
0.2899
-0.0001
-0.03%
Closed 15:33 06/30 EDT
OPEN
0.2899
PREV CLOSE
0.2900
HIGH
0.2900
LOW
0.2023
VOLUME
46.94K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
0.1113
MARKET CAP
--
P/E (TTM)
-0.1330
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENGN last week (0622-0626)?
Weekly Report · 1d ago
Weekly Report: what happened at ENGN last week (0615-0619)?
Weekly Report · 06/22 09:11
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 06/19 09:09
enGene amends filing, lifts estimated non-cash stock-comp restructuring charge to $4.7 million-$5 million
PUBT · 06/18 20:07
Midday Fly By: Trump says Apple working with Intel to design chips
TipRanks · 06/18 16:22
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Benzinga · 06/18 12:10
enGene Holdings Cut to Underweight From Equal-Weight by Morgan Stanley
Dow Jones · 06/18 10:59
Morgan Stanley Downgrades enGene Therapeutics to Underweight
Benzinga · 06/18 10:48
More
About ENGNW
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGNW stock methods without spending real money on the virtual paper trading platform.